Paper Details

  1. Home
  2. Paper Details

Uncoupling DNA damage from chromatin damage to detoxify doxorubicin.

Author: AkkermansJimmy J, ArensRamon, BakkerJeroen M, BellinMilena, BorràsDaniel M, GerhardtSophie, GiacomelliElisa, LiJunmin, LiXiaoyang, MummeryChristine L, NeefjesJacques, OrlovaValeria, OverkleeftHermen S, PangBaoxu, QiaoXiaohang, RuttenArjo, SmitLinda, SmitsAnke M, SongJi-Ying, TertoolenLeon G J, WanderDennis P A, ZuurCharlotte L, van DuikerenSuzanne, van GilsNoortje, van HerwaardenTessa, van TellingenOlaf, van der ZandenSabina Y

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Anthracycline-induced cardiotoxicity requires both DNA damage and chromatin damage, two cellular activities that can be separated chemically. Variants of anthracyclines that induce chromatin damage without causing double-strand breaks maintained similar anticancer potency, suggesting that chromatin damage is a major cytotoxic mechanism.
Paper Details　
Original Abstract of the Article :
The anthracycline doxorubicin (Doxo) and its analogs daunorubicin (Daun), epirubicin (Epi), and idarubicin (Ida) have been cornerstones of anticancer therapy for nearly five decades. However, their clinical application is limited by severe side effects, especially dose-dependent irreversible cardiot...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334570/

データ提供：米国国立医学図書館（NLM）

Uncoupling DNA Damage from Chromatin Damage to Detoxify Doxorubicin

This study delves into the complex world of chemotherapy, focusing on the potential to minimize the harmful side effects of the widely used anticancer drug doxorubicin. The authors meticulously investigate the mechanisms of doxorubicin's action, identifying two distinct pathways: DNA damage and chromatin damage. The study aims to uncouple these pathways to retain the drug's anti-cancer efficacy while minimizing its toxic side effects.

Doxorubicin: A Double-Edged Sword

Doxorubicin is a powerful weapon in the fight against cancer, but it comes with a price. Like a double-edged sword, it can both destroy cancer cells and damage healthy tissues. This study offers a groundbreaking strategy for harnessing the power of doxorubicin while minimizing its toxic impact.

A New Approach to Chemotherapy

This research represents a significant step forward in the development of safer and more effective chemotherapy treatments. The study's findings suggest that by targeting specific pathways involved in doxorubicin's action, we can retain its anti-cancer efficacy while minimizing the risk of debilitating side effects.

Dr. Camel's Conclusion

This study is a testament to the ongoing quest for more effective and safer cancer treatments. The researchers' innovative approach to uncoupling the toxic effects of doxorubicin from its anti-cancer activity offers a beacon of hope for millions of cancer patients.
Date :
  1. Date Completed 2020-09-01
  2. Date Revised 2020-09-01
Further Info :

Pubmed ID

32554494

DOI: Digital Object Identifier

PMC7334570

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.